JADENU (deferasirox) prior authorization — chronic iron overload
Customize your policy alerts
Sign up for all Mississippi Division of Medicaid policy alerts
Know when Mississippi Division of Medicaid releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization requirements and medical necessity criteria for JADENU and JADENU SPRINKLE (deferasirox) for Mississippi Division of Medicaid members; applies to prescribers requesting PA for these products.
No material clinical or coverage changes in this revision.
Coverage Criteria for JADENU (deferasirox)
Initial Authorization — Transfusion-related chronic iron overload
Covered when ALL of the following are met for the transfusion-related chronic iron overload indication:
Logical grouping includes an OR branch for documented EXJADE intolerance/failure or lactose‑intolerance‑related diarrhea as justification.
Initial Authorization — Non–transfusion-dependent thalassemia
Covered when ALL of the following are met for non-transfusion-dependent thalassemia indication:
Criteria require both clinical documentation of iron overload and supporting objective imaging or assay results.
Re-Authorization — Continuation and duration (12 months)
Re-authorization criteria (12 months):
Re-authorization requires evidence of response or stabilization.
Requests for JADENU that propose dosing above the FDA‑approved dose or that seek use in patients who do not meet the age/weight requirements in the package insert will not meet coverage criteria. Prior authorization approval requires the prescribed dose and the patient’s age/weight to conform to the FDA‑approved labeling.
Clinical requests must include the objective laboratory and imaging evidence specified in the criteria. Missing required documentation — for example, absence of the requisite serum ferritin values (two values ≥1 month apart for transfusion‑related iron overload), liver or cardiac T2* MRI or atomic absorption spectrophotometry (HIC) results where applicable, or lack of specialty prescriber documentation — may render the request not medically necessary and subject it to denial.
Provider Actions and Authorization Requirements
Prior authorization required; initial authorization duration
Prior authorization is required for JADENU and JADENU SPRINKLE. Initial authorization is for 6 months (or 12 months if there is documentation of EXJADE intolerability). Include documentation of duration requested with the PA submission.
- Initial authorization: 6 months OR 12 months with documentation of EXJADE intolerability
Step therapy: prior EXJADE trial or documented intolerance
Documented prior trial of EXJADE (deferasirox) is required unless there is documented lactose‑intolerance–related diarrhea; an EXJADE trial must be ≥ 6 months without improvement or have documented significant adverse events (e.g., prolonged fevers requiring hospitalization) to meet the step requirement.
- Failure on EXJADE defined as: trial ≥ 6 months with no improvement; OR prolonged fevers requiring hospitalization while on EXJADE; OR documentation of tissue iron concentrations with prior EXJADE treatment
- Alternate path: documented history of lactose‑intolerance diarrhea
Required documentation to support PA
Submit objective clinical documentation with the PA: patient age and weight per the FDA package insert, serial serum ferritin values, relevant tissue iron measurements (LIC/HIC or T2* MRI), and evidence of specialist involvement.
- Patient age and weight consistent with FDA indication
- Serum ferritin values (for transfusion‑related: two values >1000 mcg/L at least one month apart)
- Liver or cardiac T2* MRI results (e.g., Liver T2* ≤6.3 ms or Cardiac T2* ≤20 ms) or atomic absorption spectrophotometry (AAS) HIC results (e.g., HIC ≥70 or ≥99 micromol/g dw as applicable)
- Documentation of prior EXJADE use or intolerance when applicable
- Evidence the medication is prescribed by or in consultation with a hematologist and/or hepatologist
PA required and subject to criteria — denial risks
PA requests will be denied if the patient does not meet the policy criteria — including minimum age/weight per FDA indication, dosing within FDA‑approved limits, required laboratory/imaging thresholds, specialist prescriber requirement, or absence of documented EXJADE trial or intolerance when required.
- Minimum ages: ≥2 years for transfusion‑related indication; ≥10 years for non‑transfusion‑dependent thalassemia
- Prescribed dose must not exceed FDA‑approved dose
- Required lab/imaging thresholds (e.g., serum ferritin >1000 mcg/L on two values ≥1 month apart; LIC ≥5 mg Fe/g dw for non‑transfusion‑dependent thalassemia)
- Medication must be prescribed by or in consultation with a hematologist and/or hepatologist
- Lack of required documentation (labs, imaging, prior EXJADE trial/intolerance) may render the request not medically necessary
Clinical Thresholds and Key Laboratory Values
Definitions and Diagnostic Criteria
Background
Deferasirox (JADENU) is an oral iron chelator indicated to treat chronic iron overload due to repeated blood transfusions and for certain patients with non–transfusion‑dependent thalassemia with elevated liver iron concentration. Clinical initiation and continuation decisions are based on transfusion history and objective biomarkers such as serum ferritin and tissue iron measurements (liver or cardiac T2* MRI or AAS HIC), and dosing should follow the FDA‑approved package insert.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.